Section Review—Central & Peripheral Nervous Systems: Current and Future Therapies for Migraine

References

• HUMPHREY PPA, GOADSBY PJ: The mode of action of sumatriptan is vascular? A debate. Cephalalgia (1994) 14:401-410. An excellent review on the mechanism of action of sumatriptan.
   Google Scholar
• MOSKOWITZ MA: Neurobiology of vascular head pain. Ann. Neurol. (1984) 16:157–168.
   PubMed Web of Science ®Google Scholar
• HARDEBO JE: Vasoreactivity of the intracranial internal carotid artery. Cephalalgia (1992) 12:280–283.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L, E1CMAN R: Vasoactive pep-tide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. (1990) 38:183–187.
   Google Scholar
• MCCULLOCH J, UDDMAN R, KINGMAN TA, EDVINSSON L:Calcitonin gene-related peptide: functional role in cere-brovascular regulation. Proc. Natl. Acad. Sci. USA (1986) 83:5731–5735.
   PubMed Web of Science ®Google Scholar
• DIMITRIADOU V, BUZZI MG, THEOHARIDES TC, MOSK-OWITZ MA: Uhrastructural evidence for neurogenically-mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimula-tion. Neuroscience (1992) 48:187–203.
   PubMed Web of Science ®Google Scholar
• GRAHAM JR, WOLFF HG: Mechanism of migraine head-ache and action of ergotamine tartrate. Arch. Neurol. Psychiatry (1938) 39:736–763.
   Google Scholar
• FERRARI MD, SAXENA PR: On serotonin and migraine: aclinical and pharmacological review. Cephalalgia (1993) 13:151–165.
   PubMed Web of Science ®Google Scholar
• BEATTIE DT, CONNOR HE, FENIUK W, HUMPHREY PPA:The pharmacology of sumatriptan. Rev. Contemp. Phar-macother. (1994) 5:285–294.
   Google Scholar
• Wolff's Headache and Other Head Pain. Dalessio D, Silber-stein SD (Eds.). Oxford University Press, New York (1993). Latest edition of classic text.
   Google Scholar
• PINI LA, BERTOLOTTI M, TRENTI T, VITALE G: Dispositionof naproxen after oral administration during and be-tween migraine attacks. Headache (1993) 33:191–194.
   PubMed Web of Science ®Google Scholar
• NAPPI G, MICIELI G, TASSORELLI C, VIOTTI E, ALTAVILLAT: Effectiveness of a piroxicam fast-dissolving formula-tion sublingually administrated in the symptomatic treatment of migraine without aura. Headache (1993) 33:296–300.
   PubMed Web of Science ®Google Scholar
• DAHLOF C, BJORKMAN R: Diclofenac-K (50 and 100mg)and placebo in the acute treatment of migraine. Cepha-lalgia (1993) 13:117–123.
   PubMed Web of Science ®Google Scholar
• LARICIN GL, PRESCO'rT G: A randomised double blind,comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. Ann. Emerg. Med. (1992) 21:919–924.
   PubMed Web of Science ®Google Scholar
• RALL TW: Drugs affecting uterine motility. In: Goodmanand Gilman 's the pharmacological basis of therapeutics. Gilman AG, Rail TW, Nies AS, Taylor P (Eds.). Pergamon Press, New York (1990):933–953.
   Google Scholar
• MEYLER WJ: Side effects of ergotamine. Cephalalgia.Submitted.
   Google Scholar
• SULLIVAN JT, PRESTON Kt, TESTA MP, BUSCH M, JASINSKIDR: Psycho-activity and abuse potential of sumatriptan. Clin. Pharmacol. Tiger. (1992) 52:635–642.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD: Treatment of the migraine attack. Current Opinion in Neurology (1994) 7:258-263. Review of current thinking on treatment of the acute attack.
   Google Scholar
• PILGRIM A, BLAKEBOROUGH P: The clinical efficacy ofsumatriptan in the acute treatment of migraine. Rev. Contemp. Pharmacother. (1994) 5:295-309. Extensive up to date asessment of clinical role of sumatriptan.
   Google Scholar
• PILGRIM AJ: The clinical profile of sumatriptan: efficacy in migraine. Eur. Neurol. (1994) 34\(Suppl. 2):26–34. Comprehensive review of all current efficacy data on sumatriptan.
   Google Scholar
• TANSEY MJB, PILGRIM AJ, MARTIN PM: Long term expe-rience with sumatriptan in the treatment of migraine. Eur. Neurol. (1993) 33:310–315.
   PubMed Web of Science ®Google Scholar
• CADY RK, DEXTER J, SARGENT JD, MARKLEY H, OSTER-HAUS yr, WEBSTER CJ: Efficacy of subcutaneous suma-triptan in repeated episodes of migraine. Neurology (1993) 43:1363–1368.
   PubMed Web of Science ®Google Scholar
• BATES D, ASHFORD E, DAWSON R, ENSINK F-BM, GILHUS NE, OLESEN J, ET AL. FOR THE SUMATRIPTAN AURA STUDY GROUP: Subcutaneous sumatriptan during the migraine aura. Neurology (1994) 44:1587-1592. Surprising negative result, leading to considerable debate on the mechanism of action of sumatriptan. All other new agents will need to be so evaluated.
   Google Scholar
• SIMMONS YE, BLAKEBOROUGH P: The safety profile of sumatriptan. Rev. Contemp. Pharmacother. (1994) 5:319-328. Analysis of side-effects and long-term use of sumatriptan.
   Google Scholar
• ELLIS GC, DELANEY J, DEHART DA, OWENS A: The efficacy of metoclopramide in the treatment of migraine head-ache. Ann. Emerg. Med. (1993) 22:191-195. Controlled study taking place in the Emergency Department setting.
   Google Scholar
• MACGREGOR EA, WILKINSON M, BANCROFT K: Domperi-done plus paracetamol in the treatment of migraine. Cephalagia (1993) 13:124–127.
   PubMed Web of Science ®Google Scholar
• SAXENA PR: The pathogenesis and pharmacology of migraine. Rev. Contemp. Pharmacother. (1994) 5:259–269.
   Google Scholar
• ZIEGLER D, FORD R, KRIEGLER J, GALLAGHER RM, PER-OUTKA S, HAMMERSTAD J, ET AL.: Dihydroergotaminte nasal spray for the acute treatment of migraine. Neurol-ogy (1994) 44:447–453.
   Google Scholar
• DIAMOND S: Transnasal butorphanoL Oral presentation - 10th Migraine Trust International Symposium. London, September 1994.
   Google Scholar
• JENSEN R, BRUNCK T, OLESEN J: Prophylactic effect of sodium valproate in migraine without aura. Cephalalgia (1993) 13\(Suppl. 13):193. Promising results as a new prophylactic agent.
   Google Scholar
• HERRING R, STEINER Tj: Sodium valproate in the treatment of acute migraine attacks. Cepbalalgia (1993) 13\(Suppl. 13):98. Promising results as a new prophylactic agent.
   Google Scholar
• SAPER J, SILBERSTEIN S, LAKE A, WINTERS M: Double blind trials of fluoxetine: chronic tia fly headache and migraine. Headache (1993) 33:266-267. No great benefit of fluoxetine was demonstrated.
   Google Scholar
• FERRARI MD, TERWINDT GM, VISSER WH, REINES SA FOR THE DUTCH/US MK-462 STUDY GROUP: A placebo-con-trolled dose-ranging study of MK-462 versus sumatrip-tan in migraine. In: New Advances in Headache Research. Rose FC (Ed.). Smith-Gordon and Company Limited, London (1994) 4:5–7.
   Google Scholar
• DAHLOF C: A multicentre double-blind, placebo-con-trolled, dose ranging study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Oral presentation, 10th Migraine Trust Inter-national Symposium. London, September 1994.
   Google Scholar
• GOADSBY PJ, EDVINSSON L: Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-iu receptor agonist 311C90. Headache (1994) 34:394–399.
   PubMed Web of Science ®Google Scholar
• LEE WS, MOSKOWITZ MA: Conforrnationally-restrictedsumatriptan analogues, CP-122,288 and CP-122,638 ex-hibit enhanced potency against neurogenic inflamma-tion in dura mater. Brain Res. (1993) 626:303–305.
   PubMed Web of Science ®Google Scholar
• MOUSSAOUI SM, LEE WS, CUTRER M, BONICI B, GARRET C, MOSKOWITZ MA: RPR 100893, a novel non-peptide antagonist of the human NK: receptor: effects in two guinea-pig models of migraine; dural neurogenic in-flammation and c-fos expression induced in the CNS by nociceptive stimulations. In: New Advances in Headache Research. Rose FC (Ed.). Smith-Gordon and Company Lim-ited, London (1994) 4:327.
   Google Scholar
• Pfizer's novel analgesic enters clinic. R&D Focus Drug News. 27th April, 1992.
   Google Scholar
• OLESEN J, THOMSEN LL, IVERSEN H: Nitric oxide is a key molecule in migraine and other vascular headaches. TiPS (1994) 15:149–153.
   PubMed Web of Science ®Google Scholar
• JOUTEL A, BOUSSER M-G, BIOUSSE V, LABAUGE P, CHABRIAT H, NIBBIO A, ET AL.: A gene for familial hemiplegic migraine maps to chromosome 19. Nature Genetics (1993) 5:40-45. The genetic basis of one rare form of migraine is determined. The relevance to migraine with and without aura is not yet elucidated. Dr Michael Gross MA MD MRCP, The Royal and East Surrey Neurology Research Unit, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey, UK.
   Google Scholar